Cytochrome P-450 CYP2D6

• 

  Subject Areas on Research

  • A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. 
  • CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids. 
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. 
  • Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. 
  • Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. 
  • Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. 
  • Clinical application of cardiovascular pharmacogenetics. 
  • Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. 
  • Drug-drug-gene interaction risk among opioid users in the U.S. Department of Veterans Affairs. 
  • Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. 
  • Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators. 
  • Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. 
  • Monitoring changes in gene expression in renal ischemia-reperfusion in the rat. 
  • More than polymorphism. 
  • Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen. 
  • Pharmacogenomics for personalized pain medicine. 
  • Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. 
  • Preoperative CYP2D6 metabolism-dependent β-blocker use and mortality after coronary artery bypass grafting surgery. 
  • Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. 
  • Tafenoquine: A Step toward Malaria Elimination. 
  • Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. 
  • Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). 
  • The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice. 
• 

  Keywords of People

  • Orlando, Lori Ann, Professor of Medicine, Medicine, General Internal Medicine